⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BIIB News
Biogen Inc. Common Stock
AB2 Bio receives $30 million from Nippon Shinyaku for exclusive U.S. commercialization rights to Tadekinig Alfa
globenewswire.com
BIIB
Fraud Detection and Prevention (FDP) in BFSI Market worth $15.06 billion by 2031 - Exclusive Report by MarketsandMarkets™
prnewswire.com
MA
T
IBM
FIS
FISV
AXP
V
PYPL
COF
BK
BAC
JPM
WFC
C
MS
GS
SCHW
AXS
ALL
CB
PGR
TRV
UNM
MET
PRU
AIG
L
AIZ
SIGI
ENR
LNC
AGNC
IVZ
AMP
ICE
EQIX
AMZN
GOOGL
MSFT
NVDA
AMD
INTC
CSCO
ADBE
CRM
ORCL
SAP
ACN
GOOG
AMAT
MU
QCOM
TXN
INTU
ADP
PAYX
DXC
CTSH
INFY
WDC
SE
MELI
BABA
JD
NTES
PDD
BIDU
IQ
VIPS
XPEV
NIO
LI
LCID
RIVN
TSLA
GM
F
STLA
CHPT
BLNK
PLUG
FCEL
BE
RUN
SEDG
ENPH
CRSP
MRNA
BMY
PFE
JNJ
GILD
AMGN
BIIB
REGN
AZN
LLY
ABBV
XOM
CVX
SHEL
TTE
COP
EOG
APA
OXY
XNET
UPST
SOFI
HOOD
COIN
MP
EXAS
TDOC
ON
NXPI
MRVL
ALGN
IDXX
VRTX
SNPS
CDNS
MCHP
ADI
AVGO
LRCX
ASML
KLAC
TER
GPN
LXU
ACI
XPER
NICE
BCC
FEED
DV
Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026
prnewswire.com
BIIB
Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026
prnewswire.com
BIOA
BIIB
Form 8-K
sec.gov
BIIB
RARE Drug Development Symposium Marks 10th Anniversary with Dedicated Pitch Sessions and The Theme and Call to Action to Align Advocates, Science and Industry
prnewswire.com
BIIB
REGN
GILD
BTE
BROS
BFLY
BCTX
BCRX
BTAI
ALRS
CAPR
CRIS
CYCN
EXAS
FATE
GNTX
HRMY
INCY
IONS
KODK
LAKE
LULU
MRNA
NBIX
NTRA
OCGN
ORGN
PGEN
PLRX
RARE
RGNX
RXRX
SAVA
SGMO
SNOW
SRPT
STEM
TGTX
TLSA
TXG
VRTX
ZETA
Secretome Therapeutics Expands Rare Disease Leadership Team
businesswire.com
SRPT
RPRX
PFE
BIIB
GILD
AMGN
ATRA
Colorado’s Top Technology Executives Honored at the 2026 Colorado ORBIE Awards
globenewswire.com
BIIB
CETX
SGHC
BALL
Global Robotic Endoscopy Devices Market is Predicted to Exhibit Remarkable Growth at a CAGR of ~10% by 2034 | DelveInsight
globenewswire.com
BSX
CNMD
MDT
ISRG
JNJ
SN
TLF
BIIB
NVDA
GOOG
MSFT
Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight
globenewswire.com
JNJ
BNTX
GMAB
IMUX
INO
PDSB
AZN
GSK
MRK
BIIB
EXEL
REGN
CUE
IOBT
RAPT
PRE